Table 1.
Correlations between TAF15 expression and clinicopathological characteristics in GC patients (n = 131).
Parameters | TAF15 expression | P value | |
---|---|---|---|
Negative | Positive | ||
Total number | 38 | 93 | |
Gender | |||
Male | 27 | 73 | 0.3631+ |
Female | 11 | 20 | |
Age (year) | |||
≥ 60 | 22 | 63 | 0.2839+ |
< 60 | 16 | 30 | |
Tumor size | |||
Maximum diameter (cm) | |||
≥ 5 | 6 | 75 | <0.0001++ |
< 5 | 32 | 18 | |
Differentiation | |||
Poor | 17 | 43 | 0.8758++ |
Moderate/high | 21 | 50 | |
Pathologic stage | |||
I + II | 23 | 33 | 0.0086++ |
III + IV | 15 | 60 | |
T stage | |||
T1 + T2 | 18 | 20 | 0.0031++ |
T3 + T4 | 20 | 73 | |
N stage | |||
N0 | 16 | 25 | 0.0882++ |
N1 + N2 + N3 | 22 | 68 |
TAF15 TATA-box-binding protein-associated factor 15, GC gastric cancer.
+p values were calculated by Chi-square test.
++p values were calculated by Mann–Whitney U test.